Beactica Therapeutics

Beyond's analysis on Beactica Therapeutics

• 2026-09-22 — Beactica Therapeutics advances novel LSD1-CoREST degrader for glioblastoma into IND-enabling phase

Recent news mentioning Beactica Therapeutics

• 2026-09-22 — Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma
• 2026-09-22 — Beactica Therapeutics initiates IND-enabling studies for BEA-17, a first-in-class LSD1-CoREST degrader for glioblastoma

Appears alongside

• IND-enabling
• BEA-17
• LSD1-CoREST

Browse the full archive →